Open Study on Efficacy and Tolerability of Ciprofloxacin XR Compared with Ciprofloxacin BID in The Treatment  

Oleh:

Suhendro ; Chen, Khie ; Pohan, Herdiman T.

Jenis: Article from Journal - ilmiah nasional - terakreditasi DIKTI
Dalam koleksi: Acta Medica Indonesiana vol. 39 no. 01 (Jan. 2007), page 22.
Topik: ciprofloxacin XR; ciprofloxacin BID; typhoid fever

Ketersediaan

Perpustakaan FK Nomor Panggil: A02.K.2004.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

ABSTRACT Aim: to compare the efficacy and tolerability of ciproflaxin extended-realase and ciproflaxin intermediate release in the treatment of typhoid fever. Methods: a pospective, open labelled, clinical trial, comparing the safety and efficacy of extended-release ciprofloxacin 1000 mg once daily (Ciprofloxacin XR) and ciprofloxacin intermediate release 500 mg two times daily (Ciprofloxacin bid) was performed in adult with typhoid feva Diagnosis for typhoid fever was based on Widal serology test, blood culture and Polymerase Chain Reaction (PCR) for Salmonella typhi. A two-sided student t-test and chi-square or Fisher's exact test were usedfor the analysis of clinical responses. Results: good clinical responses were obtained in 32 subjects (14 with Intermediate release ciprofloxacin and 18 with Extended-release ciprofloxacin) and there were no failure case (0%). Day to reach defervescence in Ciprojloxacin BID (mean 3.28 days) was similar to Ciprofloxacin XR group (mean 3.72 days) with p=0.43. Mild side effects were noted in 7.1 % of subjects who received Ciprofloxacin BID compared by 22.2% in subjects who received Ciprofloxacin XR, with p=0.29. There were no moderate or severe side effects on both drugs. Conclu.vion: clinical outcomes were similar for the two treatments and both treatments were well tolerated. Once daily ciprofloxacin XR was safe, effective, and non-inferior to twice-daily ciprofloxacinlR in the treatment of typhoid fever. INTRODUCTION Typhoid fever is an acute systemic infection caused by Salmonella enterica serotype typhi or paratyphi. This disease is endemic in developing countries such as India, Southeast Asia (including Indonesia), Central America and other countries with high population, which have high urbanization and lack of proper hygiene and sanitation. I) The tluoroquinolones are widely regarded as optimal for the treatment of typhoid fever in adults. They are relatively inexpensive, well tolerated and more rapidly and reliably effective than the former first-line drugs, such as: chloramphenicol, ampicillin, amoxicillin and trimethoprim-sulfamethoxazole. The majority of isolates are still sensitive. The tluoroquinolones attain excellent tissue penetration, kill S. typhi in its intracellular station¬ary stage in monocytes/macrophages and achieve higher active drug levels in the gall bladder than other drugs. They produce a rapid therapeutic response, i.e. clearance of fever and symptoms in three to five days, and very low rates of post-treatment carriage.l.s Ciprotloxacin is a tluoroquinolone derivative which is well absorbed in 01 tract and achieves high concen¬trations in the plasma and tissue/cell and thus has potential advantages over other antimicrobials in the treatment of typoid fever (gram negative bacteria). CiprofJoxacin extended-release tablets contains ciprotloxacin, a synthetic broad-spectrum antimicrobial agent for oral administration, ciprotloxacin extended release tablets are coated, bilayer tablets consisting

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali